Specifically, studies comparing trastuzumab-sensitive with trastuzumab-resistant HER2+ breast tumors show that while the HPK particles exhibit tumor-homing capability to both tumor types, particle accumulation is higher in the trastuzumab-resistant tumors concomitant with higher HER3 levels [22]. Here, ERBB2 is linked to neoplasm.